Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06691984 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 675
- Enrollment target
- 20
- Study locations
NCT06691984 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 675 participants, above the 188-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (259% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT06691984, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 675 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG Xaluritamig
- DRUG Cabazitaxel
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- Providence Saint Jude Medical Center - Fullerton
- Cedars Sinai Medical Center - Los Angeles
- University of California Irvine - Orange
- University of California San Francisco - San Francisco
Florida
- University of Florida, College of Medicine - Gainesville
- Sylvester Comprehensive Cancer Center-Fox Building - Miami
- AdventHealth Orlando - Orlando
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Kentucky
- University of Louisville Health - James Graham Brown Cancer Center - Louisville
- Norton Cancer Institute - Louisville
Alabama
- University of Alabama at Birmingham - Birmingham
Illinois
- University of Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Michigan
- Henry Ford Hospital, Henry Ford Health Systems - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 675 participants |
| Start Date | 2024-12-09 |
| Est. Completion | 2029-07-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06691984
The ClinicalTrials.gov registry entry for NCT06691984 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 675 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 188-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (259% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Enzalutamide is the first listed.
NCT06691984 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06691984 about?
NCT06691984 is a clinical study titled "Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)". The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
What is the current status of trial NCT06691984?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 675 participants. The study started on 2024-12-09. Estimated completion is 2029-07-30.
What conditions does trial NCT06691984 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT06691984?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone (DRUG), Xaluritamig (DRUG), Cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT06691984?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06691984 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
RECRUITING · Phase 3
-
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
ACTIVE NOT RECRUITING · Phase 3
-
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.